Anti-Erk1 (pT202/pY204) + Erk2 (pT185/pY187) 抗体 [EP197Y] (ab76299)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP197Y] to Erk1 (pT202/pY204) + Erk2 (pT185/pY187)
- Suitable for: WB, IP, Dot blot, ELISA
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-Erk1 (pT202/pY204) + Erk2 (pT185/pY187) antibody [EP197Y]
Erk1 (pT202/pY204) + Erk2 (pT185/pY187) 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EP197Y] to Erk1 (pT202/pY204) + Erk2 (pT185/pY187) -
由来種
Rabbit -
特異性
This antibody detects Erk1 phosphorylated at Threonine 202 and Tyrosine 204 and Erk2 phosphorylated at Threonine 185 and Tyrosine 187. -
アプリケーション
適用あり: WB, IP, Dot blot, ELISAmore details
適用なし: Flow Cyt,ICC/IF or IHC-P -
種交差性
交差種: Mouse, Rat, Human -
免疫原
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
ポジティブ・コントロール
- WB: A431 (treated with EGF), SH-SY5Y (treated with NGF), PC-12 (treated with NGF), HeLa and NIH/3T3 whole cell lysates. IP: A431 (treated with EGF) and PC-12 (treated with NGF) whole cell lysates.
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
バッファー
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
EP197Y -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab76299の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB |
1/5000 - 1/10000. Detects a band of approximately 43, 42 kDa (predicted molecular weight: 43, 41 kDa).
|
|
IP |
1/80.
|
|
Dot blot |
Use at an assay dependent concentration.
|
|
ELISA |
Use at an assay dependent concentration.
|
特記事項 |
---|
WB
1/5000 - 1/10000. Detects a band of approximately 43, 42 kDa (predicted molecular weight: 43, 41 kDa). |
IP
1/80. |
Dot blot
Use at an assay dependent concentration. |
ELISA
Use at an assay dependent concentration. |
画像
-
Dot blot analysis of single phospho peptide pT202 (Lane 1), single phospho peptide pY204 (Lane 2), double phospho peptide pT202/pY204 (Lane 3) and non-phospho peptide (Lane 4) labelling Erk1 (pT202/pY204) + Erk2 (p185/pY187) with ab76299 at a dilution of 1/1000. A peroxidase-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody at a dilution of 1/1000.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
-
All lanes : Anti-Erk1 (pT202/pY204) + Erk2 (pT185/pY187) antibody [EP197Y] (ab76299) at 1/5000 dilution
Lane 1 : A431 whole cell lysate - untreated
Lane 2 : A431 whole cell lysate - treated with 100ng/ml EGF for 10 minutes
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/50000 dilution
Predicted band size: 43, 41 kDa
Observed band size: 44 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutesBlocking and dilution buffer: 5% NFDM/TBST.
-
All lanes : Anti-Erk1 (pT202/pY204) + Erk2 (pT185/pY187) antibody [EP197Y] (ab76299) at 1/10000 dilution
Lane 1 : SH-SY5Y whole cell lysate - untreated
Lane 2 : SH-SY5Y whole cell lysate - treated with 100ng/ml NGF for 10 minutes
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/50000 dilution
Predicted band size: 43, 41 kDa
Observed band size: 42,44 kDa why is the actual band size different from the predicted?
Exposure time: 15 secondsBlocking and dilution buffer: 5% NFDM/TBST.
-
All lanes : Anti-Erk1 (pT202/pY204) + Erk2 (pT185/pY187) antibody [EP197Y] (ab76299) at 1/10000 dilution
Lane 1 : PC-12 whole cell lysate - untreated
Lane 2 : PC-12 whole cell lysate - treated with 100ng/ml NGF for 10 minutes
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/50000 dilution
Predicted band size: 43, 41 kDa
Observed band size: 42,44 kDa why is the actual band size different from the predicted?
Exposure time: 15 secondsBlocking and dilution buffer: 5% NFDM/TBST.
-
All lanes : Anti-Erk1 (pT202/pY204) + Erk2 (pT185/pY187) antibody [EP197Y] (ab76299) at 1/10000 dilution
Lane 1 : HeLa whole cell lysate - untreated
Lane 2 : HeLa whole cell lysate - treated with Lambda Phosphatase
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/50000 dilution
Predicted band size: 43, 41 kDa
Observed band size: 42,44 kDa why is the actual band size different from the predicted?
Exposure time: 30 secondsBlocking and dilution buffer: 5% NFDM/TBST.
-
Anti-Erk1 (pT202/pY204) + Erk2 (pT185/pY187) antibody [EP197Y] (ab76299) at 1/10000 dilution + NIH/3T3 whole cell lysate at 10 µg
Secondary
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/50000 dilution
Predicted band size: 43, 41 kDa
Observed band size: 42,44 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutesBlocking and dilution buffer: 5% NFDM/TBST.
-
ab76299 at 1/80 immunoprecipitating Erk1 (pT202/pY204) + Erk2 (pT185/pY187) in A431 whole cell lysate.
Lane 1 (input): A431 whole cell lysate - treated with 100ng/ml EGF for 10 min (10µg).
Lane 2 (+): ab76299 + A431 whole cell lysate - treated with 100ng/ml EGF for 10 min.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab76299 in A431 whole cell lysate - treated with 100ng/ml EGF for 10 min.
For western blotting, ab76299 was used at a dilution of 1/1000 and a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG, was used as the secondary antibody (1/1500).
Blocking and dilution buffer: 5% NFDM/TBST.
-
ab76299 at 1/80 immunoprecipitating Erk1 (pT202/pY204) + Erk2 (pT185/pY187) in PC-12 whole cell lysate.
Lane 1 (input): PC-12 whole cell lysate - treated with 100ng/ml NGF for 10 min (10µg).
Lane 2 (+): ab76299 + PC-12 whole cell lysate - treated with 100ng/ml NGF for 10 min.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab76299 in PC-12 whole cell lysate - treated with 100ng/ml NGF for 10 min.
For western blotting, ab76299 was used at a dilution of 1/1000 and a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG, was used as the secondary antibody (1/1500).
Blocking and dilution buffer: 5% NFDM/TBST.
-
ELISA analysis of various phospho and non-phospho peptides (0-250 ng/ml) labelling Erk1 (pT202/pY204) + Erk2 (pT185/pY187) with ab76299 at a dilution of 1/1000. An Alkaline Phosphatase-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/2500).
ab76299 has stronger affinity for the double phospho peptide Y204/Y187 than to single phospho peptides T202 or Y204.
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (79)
ab76299 は 79 報の論文で使用されています。
- Dong X et al. The protective effect of gentisic acid on rheumatoid arthritis via the RAF/ERK signaling pathway. J Orthop Surg Res 17:109 (2022). PubMed: 35184721
- Liu X et al. EGF signaling promotes the lineage conversion of astrocytes into oligodendrocytes. Mol Med 28:50 (2022). PubMed: 35508991
- Yu D et al. Quercitrin protects human bronchial epithelial cells from oxidative damage. Open Med (Wars) 17:375-383 (2022). PubMed: 35799602
- Liu S et al. Low-Intensity Pulsed Ultrasound Enhanced Adipose-Derived Stem Cell-Mediated Angiogenesis in the Treatment of Diabetic Erectile Dysfunction through the Piezo-ERK-VEGF Axis. Stem Cells Int 2022:6202842 (2022). PubMed: 35935181
- Jiang H et al. Concanavalin A inhibits human liver cancer cell migration by regulating F-actin redistribution and assembly via MAPK signaling pathway. Oncol Lett 24:405 (2022). PubMed: 36276493